Company intelligence / Profile preview

Isodiol International

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~57
Development stage: Other

Overview

Isodiol has commercialized high-purity CBD ingredients and consumer products, with APIs approved by regulatory authorities (e.g., MHRA in the UK) and has conducted and participated in multiple clinical trials in neurological, pain, and dermatological indications. Prescription products (ISODERM, ISODIOLEX) are approved for epilepsy and Parkinson’s in Brazil[1][4].

Therapeutic areas: OtherNeurologyDermatology
Modalities: Small moleculeBiologicNanoemulsified formulationMicro-encapsulationActive Pharmaceutical Ingredient
Industry: Biotech

Partnerships

Canopy Growth Corporation (licensing of Pot-O-Coffee and Pot-O-Tea)Livecare Health Canada (telehealth platform for cannabis products)Cage Warriors (sports wellness partnership)

Beyond the preview

Go deeper on Isodiol International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isodiol International.

Explore the full profile